Diazepam dealers: Pharmacists sentenced for ‘industrial’ illegal supply

Mandip Sidhu and Nabeil Nasr illegally supplied more than 55 million doses of controlled drugs, the MHRA has revealed.

Sidhu attempted to trick an MHRA inspector with a fake invoice, the watchdog said

Two pharmacists have been sentenced for the “industrial scale” illegal supply of class C controlled drugs (CDs), the Medicines and Healthcare products Regulatory Agency (MHRA) announced yesterday (May 16).

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

James Stent

Read more by James Stent

James Stent joined C+D as a digital reporter in May 2023 from the South African human rights news agency GroundUp, where he was senior reporter and consultant editor.

Latest from News

Sebco coal tar scalp ointment appointed by DHSC to support current shortages

 • comment

Due to shortages in coal tar scalp ointment, the DHSC has asked the manufacturer of an equivalent product - Sebco - to provide increased stock levels to support patients during this time.

Pharmacies to boost naloxone stock amid ‘sudden’ overdose spike

 
• By 
 • comment

Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.

Cuts and commissioning: What does NHSE’s axing mean for ICBs?

 
• By 
 • comment

As the dust settles on the announcement that NHS England (NHSE) is set for the scrapheap, questions on what a 50% headcount cut means for local commissioners remain…

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.